Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

84535 reported adverse events

Drugs of this class: LAMIVUDINE LAMIVUDINE AND ZIDOVUDINE ABACAVIR AND LAMIVUDINE EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE ZIDOVUDINE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE DIDANOSINE EMTRICITABINE EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 BONE DENSITY DECREASED 7656
1 PAIN 4870
2 CHRONIC KIDNEY DISEASE 4609
3 ANXIETY 4240
4 EMOTIONAL DISTRESS 4167
5 RENAL FAILURE 4138
6 FOETAL EXPOSURE DURING PREGNANCY 4063
7 TOOTH LOSS 4030
8 ANHEDONIA 3497
9 OSTEONECROSIS 3183
See all common reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CSF HIV ESCAPE SYNDROME 83 0.9222
1 PINEALOBLASTOMA 65 0.8553
2 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 84 0.8400
3 BLOOD HIV RNA INCREASED 618 0.7601
4 IMMUNE RECONSTITUTION SYNDROME 937 0.7241
5 HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION 129 0.6789
6 VIRAL MUTATION IDENTIFIED 1280 0.6390
7 ACUTE HIV INFECTION 99 0.6149
8 MITOCHONDRIAL TOXICITY 327 0.5788
9 LIPODYSTROPHY ACQUIRED 814 0.5511
See all enriched reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]